Sharon Silverman
Internal Medicine · Columbia, MDNPI 1144296328
Payments from drug & device makers
Across 178 payments — averaging $18.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$901
- Lilly USA, LLC$320
- Kowa Pharmaceuticals America, Inc.$312
- Novo Nordisk$262
- Biohaven Pharmaceutical Holding Company Ltd.$252
- Biohaven Pharmaceuticals, Inc.$247
- plus $966 from 10 others
What the payments were for
- Food & beverage$3,15897%
- Education$1023%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 55 | $901 |
| Lilly USA, LLC | 18 | $320 |
| Kowa Pharmaceuticals America, Inc. | 28 | $312 |
| Novo Nordisk | 11 | $262 |
| Biohaven Pharmaceutical Holding Company Ltd. | 9 | $252 |
| Biohaven Pharmaceuticals, Inc. | 9 | $247 |
| Pfizer | 11 | $242 |
| GSK | 12 | $219 |
| Amarin Pharma, Inc. | 9 | $141 |
| Astellas Pharma US Inc | 4 | $141 |
| Exact Sciences | 3 | $65 |
| Merck | 2 | $39 |
| Eisai Inc. | 2 | $34 |
| Abbott | 2 | $34 |
| AstraZeneca | 2 | $30 |
| Mylan Specialty L.p. | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$104
How this compares
$3,260 in reported general payments places this provider in the 85th percentile of 2,979 internal medicine providers in Maryland.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 17 | $22,730 |
| LivaloPitavastatin Calcium | 12 | $3,861 |
| SynthroidLevothyroxine Sodium | 40 | $2,348 |
| Atorvastatin Calcium | 107 | $1,698 |
| Olmesartan Medoxomil | 54 | $1,351 |
| Levothyroxine Sodium | 75 | $930 |
| Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide | 12 | $877 |
| Losartan Potassium | 59 | $534 |
| Rosuvastatin Calcium | 54 | $523 |
| Amlodipine Besylate | 57 | $479 |
| Esomeprazole Magnesium | 19 | $451 |
| Escitalopram Oxalate | 29 | $407 |
| Tamsulosin Hcl | 15 | $297 |
| Metoprolol Succinate | 21 | $287 |
| Ipratropium Bromide | 15 | $245 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $242 | $22,73017 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $312 | $3,86112 claims |
| AbbVieSynthroid | $901 | $2,34840 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,979 internal medicine providers in Maryland.
Other internal medicine in Columbia
- Mark CorriereColumbia$402K
- Saba SheikhColumbia$342K
- William SawayColumbia$295K
- Shishir KhetanRockville$52.1M
- Steven GellerElkridge$15.1M
- Mary HowellHagerstown$6.2M
- Kristen MarroneBaltimore$5.6M
- Jonathan CohenRockville$5M
- Andrea ApoloBethesda$4.8M
- Peta-Gay Jackson BoothBaltimore$3.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.